NCT05320367View on ClinicalTrials.gov

A Study of Inhaled Cannabidiol in Healthy Occasional Cannabis Users

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

October 31, 2026

Study Completion Date

December 31, 2026

Conditions
Cannabis
Interventions
DRUG

Cannabis, placebo

Eligible participant will be randomize 1:1:1:1:1 to receive placebo, CBD (5mg, 20mg, 50mg and 100mg). Only one research product will be inhaled for each visit. The sequence will depend on the assigned randomization group.

All Listed Sponsors
lead

Centre hospitalier de l'Université de Montréal (CHUM)

OTHER

NCT05320367 - A Study of Inhaled Cannabidiol in Healthy Occasional Cannabis Users | Biotech Hunter | Biotech Hunter